As of November 6, 2026, Neuphoria Therapeutics Inc. is a publicly traded company (Nasdaq: NEUP). The largest holder reporting an active stake on Schedule 13D is Lynx1 Capital Management LP, at 16.3%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Shay Capital LLC (7.3%), AdvisorShares Trust (5.78%) (Schedule 13D/A, December 29, 2025).
Is this your company?
About to sign with, pay or invest in Neuphoria Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Neuphoria Therapeutics Inc. a real, registered company?
- Neuphoria Therapeutics Inc. files with the SEC under CIK 1191070 (its SEC filings).
- Its shares are listed under the ticker NEUP on Nasdaq (SEC company record).
- Incorporated in C3; business address in Burlington, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Neuphoria Therapeutics Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names AdvisorShares Trust (filed 2026-10-05).
Who are Neuphoria Therapeutics Inc.'s owners and officers?
Neuphoria Therapeutics Inc.: business address in Burlington, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-05 | Advisorshares Trust | 5.78% |
| Schedule 13G/A, 2026-07-28 | Coastlands Capital LP | 4.23% |
| Schedule 13G/A, 2026-02-06 | Baselake Partners, LP | 4.1% |
| Schedule 13D/A, 2025-12-29 | Lynx1 Capital Management LP | 16.3% |
| Schedule 13D/A, 2025-12-02 | Lynx1 Capital Management LP | 16.3% |
| Schedule 13D/A, 2025-11-28 | Lynx1 Capital Management LP | 16.3% |
| Schedule 13D/A, 2025-11-18 | Lynx1 Capital Management LP | 16.3% |
| Schedule 13D/A, 2025-11-10 | Lynx1 Capital Management LP | 26.5% |
| Schedule 13G, 2025-11-05 | Coastlands Capital LP | 5.1% |
| Schedule 13G, 2025-10-31 | Baselake Partners, LP | 9.4% |
| Schedule 13G, 2025-10-31 | Shay Capital LLC | 7.3% |
| Schedule 13D, 2025-10-23 | Lynx1 Capital Management LP | 37.1% |
Questions about who owns Neuphoria Therapeutics Inc.
Who owns Neuphoria Therapeutics Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Neuphoria Therapeutics Inc.: Lynx1 Capital Management LP (16.3%, Schedule 13D/A, filed 2025-12-29), Shay Capital LLC (7.3%, Schedule 13G, filed 2025-10-31) and Advisorshares Trust (5.78%, Schedule 13G, filed 2026-10-05).
Who are the largest shareholders of Neuphoria Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Neuphoria Therapeutics Inc. on this page are Lynx1 Capital Management LP (16.3%), Shay Capital LLC (7.3%) and Advisorshares Trust (5.78%).
When did Lynx1 Capital Management LP buy into Neuphoria Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lynx1 Capital Management LP on this page is the Schedule 13D, filed 2025-10-23, reporting 37.1%; its latest, Schedule 13D/A filed 2025-12-29, reports 16.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Neuphoria Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Neuphoria Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neuphoria Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Neuphoria Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Lynx1 Capital Management LP, a 10% owner: 875,328 shares (16.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-23).
- , a 10% owner: 875,328 shares (16.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-23).
Shares outstanding: 5,411,334 as of 2026-09-17, from the company's latest SEC cover page.
How much has Neuphoria Therapeutics Inc. raised?
No fundraising or offering filing from Neuphoria Therapeutics Inc. is on file with us.
Keep reading
More on Neuphoria Therapeutics Inc. and the records around it.
Neuphoria Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Baselake Partners, LP also filed stake reports on 7 other companies: KIORA PHARMACEUTICALS, INC. (Sep 2026), Passage Bio, Inc. (Jun 2026), Generation Bio Co. (Feb 2026)
- Shay Capital LLC also filed stake reports on 7 other companies: Xponential Fitness, Inc. (Jun 2026), DUOS TECHNOLOGIES GROUP, INC. (May 2026), A2Z CUST2MATE SOLUTIONS CORP. (Apr 2026)
- AdvisorShares Trust also filed stake reports on 8 other companies: PSYENCE BIOMEDICAL LTD. (Oct 2026), Silo Pharma, Inc. (Jul 2026), Enveric Biosciences, Inc. (Jan 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/neuphoria-therapeutics